Tags

Type your tag names separated by a space and hit enter

Endocannabinoids and Mental Disorders.

Abstract

Preclinical and clinical data fully support the involvement of the endocannabinoid system in the etiopathogenesis of several mental diseases. In this review we will briefly summarize the most common alterations in the endocannabinoid system, in terms of cannabinoid receptors and endocannabinoid levels, present in mood disorders (anxiety, posttraumatic stress disorder, depression, bipolar disorder, and suicidality) as well as psychosis (schizophrenia) and autism. The arising picture for each pathology is not always straightforward; however, both animal and human studies seem to suggest that pharmacological modulation of this system might represent a novel approach for treatment.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Theoretical and Applied Sciences and Neuroscience Centre, University of Insubria, Via Manara 7, 21052, Busto Arsizio, VA, Italy.

    ,

    Department of Theoretical and Applied Sciences and Neuroscience Centre, University of Insubria, Via Manara 7, 21052, Busto Arsizio, VA, Italy. Fondazione Zardi Gori, Milan, Italy.

    Department of Theoretical and Applied Sciences and Neuroscience Centre, University of Insubria, Via Manara 7, 21052, Busto Arsizio, VA, Italy. daniela.parolaro@uninsubria.it. Fondazione Zardi Gori, Milan, Italy. daniela.parolaro@uninsubria.it.

    Source

    MeSH

    Animals
    Autistic Disorder
    Brain
    Cannabinoid Receptor Agonists
    Cannabinoid Receptor Antagonists
    Endocannabinoids
    Humans
    Mood Disorders
    Psychotic Disorders
    Receptor, Cannabinoid, CB1
    Receptor, Cannabinoid, CB2
    Signal Transduction

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    26408164

    Citation

    Rubino, Tiziana, et al. "Endocannabinoids and Mental Disorders." Handbook of Experimental Pharmacology, vol. 231, 2015, pp. 261-83.
    Rubino T, Zamberletti E, Parolaro D. Endocannabinoids and Mental Disorders. Handb Exp Pharmacol. 2015;231:261-83.
    Rubino, T., Zamberletti, E., & Parolaro, D. (2015). Endocannabinoids and Mental Disorders. Handbook of Experimental Pharmacology, 231, pp. 261-83. doi:10.1007/978-3-319-20825-1_9.
    Rubino T, Zamberletti E, Parolaro D. Endocannabinoids and Mental Disorders. Handb Exp Pharmacol. 2015;231:261-83. PubMed PMID: 26408164.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Endocannabinoids and Mental Disorders. AU - Rubino,Tiziana, AU - Zamberletti,Erica, AU - Parolaro,Daniela, PY - 2015/9/27/entrez PY - 2015/9/27/pubmed PY - 2015/12/19/medline KW - Autism KW - Bipolar disorder and suicidality KW - Depression KW - Endocannabinoid system anxiety KW - Posttraumatic stress disorder KW - Schizophrenia SP - 261 EP - 83 JF - Handbook of experimental pharmacology JO - Handb Exp Pharmacol VL - 231 N2 - Preclinical and clinical data fully support the involvement of the endocannabinoid system in the etiopathogenesis of several mental diseases. In this review we will briefly summarize the most common alterations in the endocannabinoid system, in terms of cannabinoid receptors and endocannabinoid levels, present in mood disorders (anxiety, posttraumatic stress disorder, depression, bipolar disorder, and suicidality) as well as psychosis (schizophrenia) and autism. The arising picture for each pathology is not always straightforward; however, both animal and human studies seem to suggest that pharmacological modulation of this system might represent a novel approach for treatment. SN - 0171-2004 UR - https://www.unboundmedicine.com/medline/citation/26408164/Endocannabinoids_and_Mental_Disorders_ L2 - https://dx.doi.org/10.1007/978-3-319-20825-1_9 DB - PRIME DP - Unbound Medicine ER -